CAS: 101526-83-4; Sematilide
该化合物是一种化学化合物,主要因其作为抗心律剂的作用而得到承认,属于被称为三级抗心律的一类药物,用于通过延长心脏行动潜力和耐药期治疗各种类型的心律不齐度.塞马提尔德功能通过堵塞钾渠道,从而影响心脏的电动活动.该化合物的特征是其特定的分子结构,它有助于其药理特性.它通常在受控制的临床环境中使用,因为其潜在的副作用,可能包括心脏毒性和其他系统效应.和许多制药剂一样,对塞马提尔德的治疗用途需要仔细监测剂量和病人反应,以尽量减少不利影响.其开发和使用受到广泛的研究和临床试验的指导,以确保控制心律障碍的功效和安全性.
- 英文名称Sematilide
- 中文名称司马替利
- IUPAC名称N-(2-(diethylamino)ethyl)-4-(methylsulfonamido)benzamide
- 其它别名N-(Diethylaminoethyl)-4-Methylsulfoaminobenzamide; Sematilide; N-[2-(Diethylamino)Ethyl]-4-(Methanesulfonamido)Benzamide; N-(2-Diethylaminoethyl)-4-(Methylsulfonylamino)Benzamide; N-(2-(Diethylamino)Ethyl)-4-(Methylsulfonamido)Benzamide; Benzamide,N-[2-(Diethylamino)Ethyl]-4-[(Methylsulfonyl)Amino]-; N-(Diethyl-Amino-Ethyl-)-4-Mesyl-Amino-Benz-Amide
- CAS编号101526-83-4
- MFCD编号:MFCD00867100
- FDA UNII编号:0NHB13IN3R
- 分子式:C14H23N3O3S分子量:313.42
- 产品CID: 28592
- 同类组份化合物CAS101526-83-4 (free base)101526-62-9 (HCl)
- 产品分类有机原料 → 苯类化合物 → 苯取代衍生物
物理性质
MSDS等安全信息
上下游产品
1-[4-[(Methyl-Sulfonyl)Amino]Benzoyl]Aziridine 119410-16-14-(甲基磺酰胺)苯甲酸甲酯 Methyl 4-(Methanesulfonylamino)Benzoate 50790-28-8
合成工艺路线路线简述
📜4-(甲基磺酰胺)苯甲酸甲酯,N,N-二乙基乙二胺 反应生成司马替利
参考文献:合理设计4-[(甲基磺酰基)氨基]苯甲酰胺类iii类抗心律不齐药物.
标题:合理设计4-[(甲基磺酰基)氨基]苯甲酰胺类iii类抗心律不齐药物.
摘要:
Doi:10.1021/jm00388A001
专利信息
专利号:US-7115657-B2
优先权日:2000-07-12
标题:Bifunctional agents possessing antioxidant and antiarrhythmic activity
发明人：KOUFAKI MARIA; CALOGEROPOULOU THEODORA; MAKRIYANNIS ALEXANDROS
权利人:UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA
摘要:The present invention relates to novel bifunctional agents possessing antioxidant and antiarrhytmic activity, methods for the synthesis of the same and their applications in treating ischemia-reperfusion injury, as well as a variety of disorders related to free radicals and/or arrhythmias. These bifunctional drugs should preferentially segregate in the membrane and produce their antiarrhytmic effects while, at the same time, help in protecting the membrane lipids by scavenging free radicals. The present invention comprises compounds represented by Formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 are further defined
专利号:US-2014315720-A1
优先权日:2012-10-24
标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
专利号:RU-2134683-C1
优先权日:1993-12-24
标题:Aminocarboxylic acid amides, methods of their synthesis and pharmaceutical composition
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, Hashimoto K. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ J. 2002 Aug;66(8):758-62.
8: Ishii Y, Muraki K, Kurihara A, Imaizumi Y, Watanabe M. Effects of sematilide, a novel class III antiarrhythmic agent, on delayed rectifier K+ current in guinea pig atrial myocytes. Jpn J Pharmacol. 1996 Aug;71(4):361-5.
合成参考文献
参考文献:10.1254/jjp.70.129
摘要:Xue YX, Eto K, Akie Y, Hashimoto K. Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models. Jpn J Pharmacol. 1996 Feb;70(2):129–38. doi: 10.1254/jjp.70.129.
参考文献:10.1254/jjp.71.361
摘要:Ishii Y, Muraki K, Kurihara A, Imaizumi Y, Watanabe M. Effects of sematilide, a novel class III antiarrhythmic agent, on delayed rectifier K+ current in guinea pig atrial myocytes. Jpn J Pharmacol. 1996 Aug;71(4):361–5. doi: 10.1254/jjp.71.361.
参考文献:10.1007/bf02253566|10.1159/000025393
摘要:Lai L, Su M, Tseng Y, Lien W. Sensitivity of the Slow Component of the Delayed Rectifier Potassium Current (IKs) to Potassium Channel Blockers: Implications for Clinical Reverse Use-Dependent Effects. Journal of Biomedical Science. 1999 Jul 16;6(4):251–9. doi: 10.1159/000025393.
参考文献:10.1007/bf00054193
摘要:Yang T, Tande PM, Lathrop DA, Refsum H. Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle. Cardiovasc Drugs Ther. 1992 Aug;6(4):429–36. doi: 10.1007/bf00054193.
参考文献:10.1097/00005344-199401000-00005
摘要:Krafte DS, Volberg WA. Voltage Dependence of Cardiac Delayed Rectifier Block by Methanesulfonamide Class III Antiarrhythmic Agents. Journal of Cardiovascular Pharmacology. 1994 Jan;23(1):37–41. doi: 10.1097/00005344-199401000-00005.
📝 需求与反馈
尽可能描述清楚需求与问题信息
